Dyne Therapeutics (NASDAQ:DYN – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.15), FiscalAI reports. During the same period in the prior year, the business posted ($0.76) EPS.
Dyne Therapeutics Stock Up 4.1%
Shares of NASDAQ DYN traded up $0.71 during mid-day trading on Friday, reaching $18.07. The company had a trading volume of 2,359,185 shares, compared to its average volume of 2,812,952. The firm has a 50 day simple moving average of $17.70 and a two-hundred day simple moving average of $19.33. Dyne Therapeutics has a 52-week low of $14.00 and a 52-week high of $27.31. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28. The stock has a market cap of $3.37 billion, a P/E ratio of -4.98 and a beta of 1.22.
Insider Activity at Dyne Therapeutics
In other news, Director Jason P. Rhodes sold 2,160,516 shares of Dyne Therapeutics stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the sale, the director owned 428,946 shares in the company, valued at approximately $10,723,650. The trade was a 83.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Cox sold 5,658 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $18.88, for a total value of $106,823.04. Following the completion of the sale, the chief executive officer directly owned 357,507 shares of the company’s stock, valued at $6,749,732.16. The trade was a 1.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 2,598,706 shares of company stock worth $65,432,671. Insiders own 9.46% of the company’s stock.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $47.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, September 29th. Oppenheimer lowered Dyne Therapeutics from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $40.00 to $15.00 in a report on Wednesday, October 28th. Robert W. Baird cut their price target on Dyne Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a research note on Wednesday, September 9th. Morgan Stanley cut their price target on Dyne Therapeutics from $45.00 to $36.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 9th. Finally, JPMorgan Chase & Co. cut Dyne Therapeutics from a “neutral” rating to an “underweight” rating and lowered their price objective for the stock from $17.00 to $10.00 in a research report on Wednesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $31.29.
Get Our Latest Analysis on DYN
Key Headlines Impacting Dyne Therapeutics
Here are the key news stories impacting Dyne Therapeutics this week:
- Positive Sentiment: The FDA is conducting a priority review of Dyne’s biologics license application for z-rostudirsen, its exon 51 Duchenne muscular dystrophy (DMD) candidate. The FDA’s target action date is January 21, 2027, providing a defined near-term regulatory catalyst. Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
- Positive Sentiment: Management said its cash runway extends into the second quarter of 2028, providing funding visibility for ongoing development. The company also reported progress in its DMD and DM1 programs ahead of planned 2027 milestones. Dyne Therapeutics Reports Q3 2026 Results; Advances DMD And DM1 Programs Ahead Of 2027 Milestones
- Neutral Sentiment: A valuation commentary raised the possibility that DYN is undervalued, citing its pipeline and the FDA priority review, but this is an opinion rather than a new company development. Is Dyne Therapeutics (DYN) Undervalued After Wider Losses And FDA Priority Review?
- Negative Sentiment: Third-quarter EPS was a loss of $1.06, wider than analysts’ expected $0.91 loss and the $0.76 loss a year earlier. Reports attributed the increased loss to higher research and development spending, highlighting rising development costs. Dyne Therapeutics Q3 Loss Widens On Higher R&D Costs; Cash Runway Extends Into Q2 2028
About Dyne Therapeutics
Dyne Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for serious muscle diseases. The company’s research is centered on conditions in which the delivery of therapeutic molecules to skeletal muscle and other tissues is a significant challenge.
Dyne uses its proprietary FORCE platform to design targeted therapies intended to improve the delivery of oligonucleotides into muscle cells. The platform incorporates antibodies that bind to the transferrin receptor, which can help transport genetic medicines across cell membranes and into muscle tissue.
Dyne’s pipeline includes DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.
Featured Stories
- Five stocks we like better than Dyne Therapeutics
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
